]>
IRCT20240903062942N1 IRCT 2024-09-27 Tehran University of Medical Sciences Effect of deep brain stimulation in treatment of Alzheimer's disease Evaluating the effect of deep brain stimulation (DBS) on neuropsychiatric tests parameters deviation and hippocampal volumetry in patients with Alzheimer's disease (AD) 2024-09-22 anticipated 4 Complete https://irct.ir/trial/78862 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. N/A Alzheimer's disease. Intervention group: Deep Brain Stimulation. Yes - There is a plan to make this available What will be shared: All patient's information included in the trial will be shared after making the personal data undetectable for each participant When: Data access phase will be started right after the publication To whom: Researchers working in universities research labs or related scientific organizations Conditions: Just for investigatin the accuracy of published content and also as an answer for inquiries raised from published article Where to obtain: Ramtin Pourahmad; Tel: 09144857404; E-mail: Ramtinpourahmad79@gmail.com Dr. Abbas Tafakhori; E-mail: a_tafakhori@sina.tums.ac.ir How to obtain: After requesting for data access the requested documents will be shared after inspecting the access competemcy. Comments:
public Ramtin Pourahmad
Amirebrahim ave., Ensafi alley, nastaram deadend, No1, floor 2
Tehran Iran (Islamic Republic of) 1473164143 +98 21 4489 7836 Ramtinpourahmad79@gmail.com Tehran University of Medical Sciences scientific Abbas Tafakhori
Neurology department, Imam Khomeini Hospital Complex, Keshavarz blvd, Tehran
Tehran Iran (Islamic Republic of) +98 21 4489 7836 Ramtinpourahmad79@gmail.com Tehran University of Medical Sciences Iran (Islamic Republic of) Patients with possible Alzheimer's criteria according to the National Alzheimer's Institute and CDR global scales and ADAS Cog 11 45 years 80 years Both G30.9 Alzheimer's disease, unspecified Treatment - Surgery Intervention group: Deep Brain Stimulation Neuropsychological cognition disorder. Timepoint: Measurement of cognitional disorders at First (before surgery), 6 and 12 month after procedure. Method of measurement: MMSE clinical test. Neuropsychological cognition disorder. Timepoint: At first (before procedure), 6 and 12 month after procedure. Method of measurement: ADAS-cog clinical test. Hippocampal volumetry. Timepoint: At first (before procedure), 6 and 12 month after procedure. Method of measurement: MRI. CSF Beta Amyloid. Timepoint: At first (before procedure), 6 and 12 month after procedure. Method of measurement: ELISA test. Tehran University of Medical Sciences Approved 2024-08-31 Ethics committee of Tehran University of Medical Sciences No. 1, Nastaran deadend, Ensafi alley, Amir Ebrahim Ave., Bagh Feiz, Tehran Tehran Tehran Iran (Islamic Republic of)